Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541812 | 0.77 | — | — | |
| SCHEMBL1583500 | 0.77 | — | — | |
| SCHEMBL2146082 | 0.77 | — | — | |
| SCHEMBL12540659 | 0.76 | POLB (0.35) | SMN1; SMN2 | |
| SCHEMBL2939787 | 0.76 | — | — | |
| SCHEMBL1015506 | 0.75 | — | — | |
| SCHEMBL17085695 | 0.74 | CHRNB2 (0.33) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17085680 | 0.73 | MME (0.33) | — | |
| SCHEMBL963002 | 0.73 | — | — | |
| SCHEMBL154523 | 0.73 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | SMN1; SMN2 2779/4885TP53 1904/4885GAA 1543/4885 |
| US-20110224225-A1 | Inhibitors of protein kinases | CDK1, CDK2, CDK3 | SMN1; SMN2 2779/4885TP53 1904/4885GAA 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.